Table 1 Patient characteristics.

From: Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Variable

Global series (N = 413)

Transplant-eligible (N = 228)

Transplant-ineligible (N = 149)

Asymptomatic (N = 36)

Sex

 Men

54.5%

62.1%

45.8%

54.8%

 Women

45.5%

37.9%

54.2%

45.2%

Age

64 years (37−91)

59 years (37−69)

72 years (48−91)

60 years (42−77)

IgH

 IgG

59.4%

55.8%

62.8%

42.3%

 IgA

32.8%

35.5%

30.4%

50%

 Bence−Jones

6.9%

7.0%

6.8%

7.7%

 Nonsecretory

0.9%

1.7%

0%

0%

IgL

 Kappa chain

62.5%

63.5%

60.7%

50%

 Lambda chain

37.5%

36.5%

39.3%

50%

Calcium

9.63 ± 1.72 mg/dL (0.45−17)

9.50 ± 1.99 mg/dL (0.45−17)

9.78 ± 1.37 mg/dL (2.28−14.4)

9.11 ± 0.49 mg/dL (8−10)

Creatinine

1.16 ± 0.84 mg/dL (0.20−6.50)

1.11 ± 0.76 mg/dL (0.20−6.50)

1.21 ± 0.93 mg/dL (0.36−5.90)

0.89 ± 0.28 mg/dL (0.50−1.61)

Albumin

3.52 ± 0.67 g/dL (1.43−5.50)

3.54 ± 0.73 g/dL (1.70−5.14)

3.51 ± 0.61 g/dL (1.43−5.50)

3.76 ± 0.46 g/dL (2.20−4.60)

β2 microglobulin

5.17 ± 5.22 mg/L (0−62)

5.11 ± 5.45 mg/L (0−62)

5.20 ± 4.98 mg/L (0.15−43.40)

2.25 ± 1.13 mg/L (0.30−4.41)

Hemoglobin

10.54 ± 1.98 g/dL (4.90−15.60)

10.55 ± 1.99 g/dL (5.50−15.50)

10.56 ± 1.97 g/dL (4.90−15.60)

12.38 ± 1.13 g/dL (10.10−14.70)

R-ISSa

 Stage I

19.1%

24.1%

13.1%

61.9%

 Stage II

69.7%

62.8%

77.9%

38.1%

 Stage III

11.2%

13.1%

9.0%

0%

ECOG

 0

23.8%

27.6%

20.3%

66.7%

 1

49.7%

49.3%

50.7%

33.3%

 2

20.2%

17.8%

21.6%

0%

 3

4.0%

4.6%

3.4%

0%

 4

2.3%

0.7%

4.1%

0%

Bone lesions

 None

19.2%

19.7%

18.9%

100%

 Minor lesions

42.1%

45.4%

38.5%

0%

 Major lesions

38.7%

34.9%

42.7%

0%

Plasmacytoma

11.2%

14.1%

8.3%

0%

High LDH

15%

16.6%

13.3%

5.4%

t(11;14)

13.2%

7.4%

18.1%

3.4%

t(4;14)

11.7%

12.2%

9.4%

19.4%

t(14;16)

3%

4.6%

1%

6.9%

17p abnormalities

7%

7.1%

7.2%

4.3%

HR cytogenetics

20.3%

21.6%

16.5%

29.6%

1q gain

47.7%

46.4%

50%

26.3%

del1p

5.7%

7.2%

3%

20%

  1. Clinical features were compared distinguishing between symptomatic (transplant-candidates and noncandidates) and smoldering myeloma patients.
  2. IgH immunoglobulin heavy chain, IgL immunoglobulin light chain, R-ISS Revised International Staging System, ECOG Eastern Cooperative Oncology Group Performance Status, LDH lactate dehydrogenase, HR cytogenetics high-risk cytogenetics.
  3. aProportions of each ISS group are shown instead of the R-ISS for asymptomatic myeloma patients.
Back to article page